Document is current
Any future updates will be listed below
-
Authors
Rolles, Benjamin https://orcid.org/0000-0002-7393-861X
Filho, Cilomar Martins de Oliveira https://orcid.org/0000-0002-3317-0837
Fergusson, Nathan
Bewersdorf, Jan Philipp https://orcid.org/0000-0003-3352-0902
Keating, Julia
Perkins, Cecelia
Schwede, Matthew https://orcid.org/0000-0002-0778-9230
England, James https://orcid.org/0000-0002-9692-1634
Luskin, Marlise R. https://orcid.org/0000-0002-5781-4529
DeAngelo, Daniel J. https://orcid.org/0000-0001-7865-2306
Shimony, Shai https://orcid.org/0000-0001-7245-9652
Faiz, Mifra
Hillerbrand, Addison C.
Kim, Chulwoo
Weeks, Lachelle D. https://orcid.org/0000-0001-8726-6212
Waldman, Lauren
Wazir, Mohammed
How, Joan https://orcid.org/0000-0002-6421-0117
Marneth, Anna E. https://orcid.org/0000-0001-9065-0581
Liu, Yiwen
Aryee, Martin J.
Rampal, Raajit
Tsai, Harrison K.
Gotlib, Jason https://orcid.org/0000-0001-8253-6156
Gupta, Vikas https://orcid.org/0000-0002-1419-8607
Stahl, Maximilian
Mullally, Ann https://orcid.org/0000-0001-9727-8495
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (Mildred-Scheel scholarship No.70114570)
Honoraria from GSK and Novartis
U.S. Department of Health & Human Services | National Institutes of Health (R01HL131835, R01 HL167139)
U.S. Department of Defense (W81XWH2110909)
Starr Foundation (I15-0026)
- License Information
-
More Information
Article History
Received: 2 September 2025
Revised: 6 January 2026
Accepted: 2 February 2026
First Online: 24 February 2026
Competing interests
: MJA has financial interests in SeQure Dx. MS served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi and Syndax, Kura; consulted for Boston Consulting, GLG and Dedham group and participated in CME activity for Novartis, Curis Oncology, Haymarket Media and Clinical Care Options and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. AM has received research funding from Morphic and Incyte and has consulted for Cellarity.
: Approval by the Institutional Review Board (IRB) at each participating center was obtained according to their local policies. All participating centers signed a data transfer and use agreement with DFCI.
